Synapse - Works

Results (116149)

Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)

Meeting Abstract

Rimassa, L.; Kelley, R. K.; Meyer, T.; Ryoo, B. Y.; Merle, P.; Park, J. W.; Blanc, J. F.; Lim, H. Y.; Tran, A.; Borgman-Hagey, A. E.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer

Meeting Abstract

Hyman, D. M.; Tan, D. S. W.; van Tilburg, C. M.; Albert, C. M.; Geoerger, B.; Farago, A. F.; Laetsch, T. W.; Kummar, S.; Doz, F.; Lassen, U. N.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours

Meeting Abstract

Govindan, R.; Fakih, M. G.; Price, T. J.; Falchook, G. S.; Desai, J.; Kuo, J. C.; Strickler, J. H.; Krauss, J. C.; Li, B. T.; Denlinger, C. S.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Safety profile of tepotinib in patients with advanced solid tumors: Pooled analysis of phase I and II data

Meeting Abstract

Decaens, T.; Ryoo, B. Y.; Falchook, G. S.; Veillon, R.; Doi, T.; Yamazaki, K.; Hong, D.; Qin, S.; Scheele, J.; Bruns, R.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Results from a randomised phase I/II trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)

Meeting Abstract

Voss, M. H.; Azad, A. A.; Hansen, A. R.; Gray, J. E.; Welsh, S. J.; Achour, I.; Hu, H.; Lewis, L.; Walcott, F. L.; Oosting, S. F.
Annals of Oncology (2019)

Fulltext@MSK | Save

Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt)

Meeting Abstract

Rousseau, B. J. C.; Cohen, J.; Calderaro, J.; Dupuy, A.; Bourgoin, R.; Tournigand, C.; Baumgaertner, I.; Ropert, S.; Thirot Bidault, A.; Klotz, C.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations

Meeting Abstract

Turner, N. C.; Laird, A. D.; Telli, M. L.; Rugo, H. S.; Mailliez, A.; Ettl, J.; Grischke, E. M.; Mina, L. A.; Balmaña, J.; Fasching, P. A.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

METEOR-1: A phase I study GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours

Meeting Abstract

Siu, L. L.; Rasco, D. W.; Postel Vinay, S.; Martin Romano, P.; Menis, J.; Opdam, F. L.; Heinhuis, K. M.; Egger, J. L.; Gorman, S. A.; Parasrampuria, R.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial

Meeting Abstract

Strickler, J. H.; Zemla, T.; Ou, F. S.; Cercek, A.; Wu, C.; Sanchez, F. A.; Hubbard, J.; Jaszewski, B.; Bandel, L.; Schweitzer, B.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses

Meeting Abstract

Tempero, M. A.; Reni, M.; Riess, H.; O'Reilly, E. M.; Krishnamurthi, S.; Österlund, P.; Ales-Diaz, I. C.; Milella, M.; Siena, S.; Tabernero, J.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save